Altum Sequencing Recognized by Healthstart Madrid+d for its Contribution to Healthcare Innovation
- Altum Sequencing
- Jun 24
- 2 min read
Company honoured in the Biotech/Pharma category during the 10th Anniversary of healthstart madri+d, marking a decade of support for healthcare innovation in Madrid
Altum Sequencing has been recognized in the Biotech/Pharma category during the 10th Anniversary of healthstart madri+d, an event celebrating a decade of support for healthcare innovation across the Madrid region.
The ceremony took place at Hospital Gregorio Marañón, bringing together institutions, hospitals, research organizations, universities, and companies that have contributed to the growth of Madrid's healthcare innovation ecosystem. Representing Altum Sequencing, CEO & Co-founder Marina Planas received the recognition on behalf of the whole team.
A Recognition Rooted in Clinical Origin
For Altum Sequencing, this recognition carries particular significance. The company was born at Hospital Universitario 12 de Octubre, created from a clinical need identified by doctors who envisioned a better way to monitor cancer through genomics.
That hospital origin continues to shape Altum's approach today: developing molecular monitoring technology designed to answer real clinical questions, in close collaboration with the physicians and researchers who identified the need in the first place.
Supporting Madrid's Healthcare Innovation Ecosystem
The healthstart madri+d initiative, promoted by Fundación para el Conocimiento madri+d and the Comunidad de Madrid, has spent the past decade supporting hospital-born projects on their path from clinical insight to real-world impact. Altum Sequencing's recognition reflects that trajectory — from an idea developed within a hospital research environment to a company now active in international scientific congresses and building partnerships across Europe.
Altum Sequencing extends its thanks to Fundación para el Conocimiento madri+d, the Comunidad de Madrid, healthstart madri+d, and everyone involved in promoting healthcare innovation and supporting hospital-born projects on their path to real-world impact.
A Decade of Innovation, A Continuing Journey
This recognition adds to a growing list of milestones for Altum Sequencing as the company continues to expand its footprint among pharma and biotech partners, hematologists, and clinical researchers. It also reinforces Madrid's role as a hub for healthcare innovation — one where hospital-born ideas can grow into companies with the potential to impact cancer patients worldwide.
Altum Sequencing is a precision oncology company based in Madrid, Spain, developing ctDNA-based liquid biopsy technology for cancer monitoring. Spun off from Hospital Universitario 12 de Octubre, the company's platform supports minimal residual disease detection and longitudinal treatment monitoring across a range of oncology indications.
Comments